Aura Biosciences Inc · Q1 2023 earnings

Briefing

Reported financial results for the first quarter ended March 31, 2023, and provided clinical development and operational highlights.

Aura Biosciences reported its Q1 2023 financial results, highlighting FDA guidance supporting their global Phase 3 trial and the completion of enrollment in their Phase 2 trial. The company's cash and cash equivalents totaled $173.5 million, expected to fund operations into 2025.

• FDA provided guidance supporting the global Phase 3 trial in early-stage choroidal melanoma.
• Enrollment is complete in the Phase 2 trial in choroidal melanoma using suprachoroidal route of administration.
• Planning to initiate a potentially registration-enabling Phase 3 clinical trial in 1H 2023 to evaluate the safety and efficacy of Belzupacap Sarotalocan (bel-sar) for the first-line treatment of adult patients with early-stage choroidal melanoma.
• As of March 31, 2023, Aura had cash and cash equivalents and marketable securities totaling $173.5 million.

Headline financials

Revenue & EPS history

Aura believes its current cash and cash equivalents and marketable securities are sufficient to fund its operations into 2025.